Open-Label Neoadjuvant Pembrolizumab Plus Cetuximab in Betel Nut-Associated Locally Advanced Oral Cavity Squamous Cell Carcinoma
Clinical trial NCT07733466 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07733466
- Sponsor
- Peter Brett, MD
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-08-15
- Primary completion
- 2030-07-01
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.